TradeFlare's AI research teams analysed DNTH on 9 market nights between April 29, 2026 and September 3, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 3, 2026 | BUY | $106.24 | $122.18 / $90.30 | -1.5% | -18.2% | The stock is in an uptrend, but the technicals are mixed, suggesting a short-to-medium term trade. |
| September 1, 2026 | BUY | $105.61 | $121.40 / $89.77 | +0.4% | -17.4% | The technical setup suggests a short-term mean reversion play, while the fundamental and sentiment support a longer-term bullish outlook. |
| August 31, 2026 | BUY | $105.84 | $115.00 / $87.42 | +3.3% | -17.5% | The bullish fundamental and sentiment outlook, coupled with a technical oversold bounce signal, suggests a multi-week recovery potential. |
| May 15, 2026 | HOLD | $85.34 | — / — | +0.4% | -4.2% | Positive clinical trial and FDA developments |
| May 13, 2026 | BUY | $86.15 | — / — | +3.5% | -10.8% | The stock is currently consolidating and requires a clear catalyst to break out of its range. |
| May 12, 2026 | BUY | $87.12 | — / — | -0.6% | -11.3% | Continued positive clinical trial data for lead drug candidates. |
| May 11, 2026 | BUY | $86.71 | — / — | -4.0% | -2.9% | The stock is consolidating near resistance, and while fundamentals and sentiment are bullish, technicals are neutral and risk is high. |
| April 30, 2026 | BUY | $83.50 | — / — | -2.6% | +5.9% | Positive clinical trial data readouts for lead drug candidates. |
| April 29, 2026 | BUY | $83.67 | — / — | +8.3% | +8.8% | The current technical picture is neutral to bearish, and while fundamentals and sentiment are bullish, the high risk score and conflicting technical signals warrant caution. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.